GOALS: To report our experience with pegylated interferon and ribavirin treatment of hepatitis C virus (HCV) RNA-positive inmates at the Rhode Island Department of Corrections. BACKGROUND: An estimated 1 out of 3 HCV-infected individuals will spend time in a jail or prison within a 1-year period, making prisons a unique setting for management of chronic HCV. STUDY: Chart review of all inmates identified as having initiated HCV treatment between October 2000 and April 2004. HCV-infected individuals were identified by HCV antibody screening at intake for known risk factors, elevated aminotransferase levels, or per individual request. Treatment followed standard guidelines with weight-based dosing of pegylated interferon-alpha2b and ribavirin. End points were completion of therapy plus 6 months for sustained virologic response (SVR), therapy discontinuation, and loss to follow-up. RESULTS: The cohort included 71 male patients, was mostly white (80%), and genotype 1 (65%). All 9 African Americans (AA) had genotype 1. Of 59 patients having liver biopsy, 41 had early stage disease. Overall SVR was 28%. Response rate was lower for genotype 1 compared with genotypes 2 and 3 (SVR 18% vs. 60% and 50%). Of inmates with genotype 1, no difference existed in treatment response by race (SVR 22% AA vs. 18% white). Thirty-three patients completed treatment, 26 stopped for side effects, and 5 for initial nonresponse. Eleven were lost to follow-up. CONCLUSIONS: Acceptable HCV treatment outcomes can be achieved in prisons. Our small study indicates no difference in treatment response by AA versus white race for genotype 1.
GOALS: To report our experience with pegylated interferon and ribavirin treatment of hepatitis C virus (HCV) RNA-positive inmates at the Rhode Island Department of Corrections. BACKGROUND: An estimated 1 out of 3 HCV-infected individuals will spend time in a jail or prison within a 1-year period, making prisons a unique setting for management of chronic HCV. STUDY: Chart review of all inmates identified as having initiated HCV treatment between October 2000 and April 2004. HCV-infected individuals were identified by HCV antibody screening at intake for known risk factors, elevated aminotransferase levels, or per individual request. Treatment followed standard guidelines with weight-based dosing of pegylated interferon-alpha2b and ribavirin. End points were completion of therapy plus 6 months for sustained virologic response (SVR), therapy discontinuation, and loss to follow-up. RESULTS: The cohort included 71 male patients, was mostly white (80%), and genotype 1 (65%). All 9 African Americans (AA) had genotype 1. Of 59 patients having liver biopsy, 41 had early stage disease. Overall SVR was 28%. Response rate was lower for genotype 1 compared with genotypes 2 and 3 (SVR 18% vs. 60% and 50%). Of inmates with genotype 1, no difference existed in treatment response by race (SVR 22% AA vs. 18% white). Thirty-three patients completed treatment, 26 stopped for side effects, and 5 for initial nonresponse. Eleven were lost to follow-up. CONCLUSIONS: Acceptable HCV treatment outcomes can be achieved in prisons. Our small study indicates no difference in treatment response by AA versus white race for genotype 1.
Authors: Grace E Macalino; David Vlahov; Stephanie Sanford-Colby; Sarju Patel; Keith Sabin; Christopher Salas; Josiah D Rich Journal: Am J Public Health Date: 2004-07 Impact factor: 9.308
Authors: Mitchell L Shiffman; Adrian M Di Bisceglie; Karen L Lindsay; Chihiro Morishima; Elizabeth C Wright; Gregory T Everson; Anna S Lok; Timothy R Morgan; Herbert L Bonkovsky; William M Lee; Jules L Dienstag; Marc G Ghany; Zachary D Goodman; James E Everhart Journal: Gastroenterology Date: 2004-04 Impact factor: 22.682
Authors: Stephanos J Hadziyannis; Hoel Sette; Timothy R Morgan; Vijayan Balan; Moises Diago; Patrick Marcellin; Giuliano Ramadori; Henry Bodenheimer; David Bernstein; Mario Rizzetto; Stefan Zeuzem; Paul J Pockros; Amy Lin; Andrew M Ackrill Journal: Ann Intern Med Date: 2004-03-02 Impact factor: 25.391
Authors: Richard K Sterling; Charlotte M Hofmann; Velimir A Luketic; Arun J Sanyal; Melissa J Contos; A Scott Mills; Mitchell L Shiffman Journal: Am J Gastroenterol Date: 2004-05 Impact factor: 10.864
Authors: John T Nguyen; Josiah D Rich; Bradley W Brockmann; Fred Vohr; Anne Spaulding; Brian T Montague Journal: J Urban Health Date: 2015-08 Impact factor: 3.671
Authors: Lynn E Taylor; Michaela A Maynard; Peter D Friedmann; Cynthia J Macleod; Josiah D Rich; Timothy P Flanigan; Diana L Sylvestre Journal: J Addict Med Date: 2012-09 Impact factor: 3.702
Authors: John P Rice; David Burnett; Helena Tsotsis; Mary J Lindstrom; Daniel D Cornett; Patricia Voermans; Jill Sawyer; Rob Striker; Michael R Lucey Journal: Hepatology Date: 2012-10 Impact factor: 17.425
Authors: Madeline K Mahowald; Sarah Larney; Nickolas D Zaller; Nicholas Scharff; Lynn E Taylor; Curt G Beckwith; Amanda Noska; Josiah D Rich; Timothy P Flanigan Journal: J Correct Health Care Date: 2016-01
Authors: Andrés Marco; José J Antón; Joan Trujols; Pablo Saíz de la Hoya; José de Juan; Inmaculada Faraco; Joan A Caylà Journal: BMC Infect Dis Date: 2015-08-19 Impact factor: 3.090